Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

This study is part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequencing Program. TOPMed is part of a broader Precision Medicine Initiative, which aims to provide disease treatments that are tailored to an individual's unique genes and environment. TOPMed will contribute to this initiative through the integration of whole-genome sequencing (WGS) and other -omics (e.g., metabolic profiles, protein and RNA expression patterns) data with molecular, behavioral, imaging, environmental, and clinical data. In doing so, this program aims to uncover factors that increase or decrease the risk of disease, to identify subtypes of disease, and to develop more targeted and personalized treatments. Two genotype call sets derived from WGS are now available, Freeze 8 (GRCh38) and Freeze 9b (GRCh38), with largely overlapping sample sets. Information about how to identify other TOPMed WGS accessions for cross-study analysis, as well as descriptions of TOPMed methods of data acquisition, data processing and quality control, are provided in the accompanying documents, "TOPMed Whole Genome Sequencing Project - Freeze 8, Phases 1-4" and "TOPMed Whole Genome Sequencing Project - Freeze 9b, Phases 1-4". Please check the study list at the top of each of these methods documents to determine whether it applies to this study accession.

ECLIPSE was a longitudinal observational study of 2164 COPD subjects and a smaller number of smoking controls (337) and nonsmoking controls (245) followed regularly for three years, with three chest CT scans (at baseline, one year, and three years) (Vestbo et al., 2008, PMID: 18216052). Subjects were enrolled at clinical centers in the US, Canada, Europe, and New Zealand. Inclusion criteria included subjects ages 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases) or normal spirometry with post-bronchodilator FEV1 >85% (predicted) and FEV1/FVC>0.7 (controls). Study visits were performed at enrollment, three months, and every six months thereafter with spirometry, questionnaires, and other clinical evaluations. The ECLIPSE CT scans have been analyzed with the VIDA software for emphysema and airway phenotypes. ECLIPSE has provided key insights into the clinical epidemiology of COPD, including COPD exacerbations (Hurst, et. al., 2010, PMID: 20843247) and lung function decline in COPD (Vestbo, et. al., 2011, PMID: 21991892). ECLIPSE has been used in a number of genetic studies of COPD susceptibility and protein biomarkers (Faner, et. al., 2014, PMID: 24310110). Genome-wide gene expression microarray data are available in 147 induced sputum samples from COPD subjects and 248 peripheral blood samples from COPD and control subjects.

Phenotype data for ECLIPSE subjects is available through dbGaP phs001252.

Authorized Access
Publicly Available Data (Public ftp)
Study Inclusion/Exclusion Criteria

  • Inclusion criteria included subjects ages 40-75, at least 10 pack-years of smoking, and spirometry in GOLD grades 2-4 (COPD cases), or normal spirometry with post-bronchodilator FEV1 >85% (predicted) and FEV1/FVC>0.7 (controls).
  • Exclusion criteria included respiratory disorders other than COPD, known severe α1-antitrypsin deficiency, history of significant inflammatory disease other than COPD, a COPD exacerbation or blood transfusion within 4 weeks of enrollment, prior lung surgery, recent diagnosis of cancer, inability to walk, and therapy with oral corticosteroids at inclusion.

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Genome Sequencing Illumina HiSeq 2000 N/A N/A
Study History

The ECLIPSE study protocol was finalized in 2005, and subject recruitment began in 2006.

Selected publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Links to Related Resources
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Edwin K. Silverman, MD, PhD. Brigham and Women's Hospital, Boston, MA, USA.
  • Funding Source
    • GlaxoSmithKline.
  • ECLIPSE Investigators
    • Y. Ivanov, Pleven. Pleven, Bulgaria.
    • K. Kostov. Sofia, Bulgaria.
    • J. Bourbeau. Montreal, Canada.
    • M. Fitzgerald. Vancouver, BC, Canada.
    • P. Hernandez. Halifax, NS, Canada.
    • K. Killian. Hamilton, ON, Canada.
    • R. Levy. Vancouver, BC, Canada.
    • F. Maltais. Montreal, Canada.
    • D. O'Donnell. Kingston, ON, Canada.
    • J. Krepelka. Prague, Czech Republic.
    • J. Vestbo. Hvidovre, Denmark.
    • E. Wouters. Horn-Maastricht, The Netherlands.
    • D. Quinn. Wellington, New Zealand.
    • P. Bakke. Bergen, Norway.
    • M. Kosnik. Golnik, Slovenia.
    • A. Agusti. P. de Mallorca, Spain.
    • J. Sauleda. P. de Mallorca, Spain.
    • Y. Feschenko. Kiev, Ukraine.
    • V. Gavrisyuk. Kiev, Ukraine.
    • L. Yashina. Kiev, Ukraine.
    • N. Monogarova. Donetsk, Ukraine.
    • P. Calverley. Liverpool, United Kingdom.
    • D. Lomas. Cambridge, United Kingdom.
    • W. MacNee. Edinburgh, United Kingdom.
    • D. Singh. Manchester, United Kingdom.
    • J. Wedzicha. London, United Kingdom.
    • A. Anzueto. San Antonio, TX, USA.
    • S. Braman. Providence, RI, USA.
    • R. Casaburi. Torrance CA, USA.
    • B. Celli. Boston, ME, USA.
    • G. Giessel. Richmond, VA, USA.
    • M. Gotfried. Phoenix, AZ, USA.
    • G. Greenwald. Rancho Mirage, CA, USA.
    • N. Hanania. Houston, TX, USA.
    • D. Mahler. Lebanon, NH, USA.
    • B. Make. Denver, USA.
    • S. Rennard. Omaha, NE, USA.
    • C. Rochester. New Haven, CT, USA.
    • P. Scanlon. Rochester, MN, USA.
    • D. Schuller. Omaha, NE, USA.
    • F. Sciurba. Pittsburgh, PA, USA.
    • A. Sharafkhaneh. Houston, TX, USA.
    • T. Siler. St. Charles, MO, USA.
    • E. Silverman. Boston, ME, USA.
    • A. Wanner. Miami, FL, USA.
    • R. Wise. Baltimore, MD, USA.
    • R. ZuWallack. Hartford, CT, USA.
  • ECLIPSE Steering Committee
    • H. Coxson. Canada.
    • C. Crim. GlaxoSmithKline, USA.
    • L. Edwards. GlaxoSmithKline, USA.
    • D. Lomas. UK.
    • W. MacNee. UK.
    • E. Silverman. USA.
    • J. Yates. GlaxoSmithKline, USA.
  • ECLIPSE Steering Committee. Co-Chairs
    • R. Tal Singer. GlaxoSmithKline, USA.
    • J. Vestbo. Denmark.
  • ECLIPSE Scientific Committee
    • A. Agusti. Spain.
    • P. Calverley. UK.
    • B. Celli. USA.
    • C. Crim. GlaxoSmithKline, USA.
    • B. Miller. GlaxoSmithKline, USA.
    • S. Rennard. USA.
    • R. Tal-Singer. GlaxoSmithKline, USA.
    • E. Wouters. The Netherlands.
    • J. Yates. GlaxoSmithKline, USA.
  • ECLIPSE Scientific Committee. Chair
    • W. MacNee. UK.